Last updated: February 14, 2026
What is NDC 00143-9726?
NDC 00143-9726 corresponds to Daptomycin for injection (marketed as Cubicin), an antibiotic used primarily to treat complicated skin infections, endocarditis, and bloodstream infections caused by susceptible bacteria. Produced by MSD (Merck & Co.), it received FDA approval for intravenous use.
Market Overview
Market Size (2022-2023):
- The global antibiotics market was valued at approximately $50 billion in 2022.
- Daptomycin's segment accounts for an estimated $500 million of this total, reflecting its niche use in resistant infections.
- Hospital-based treatment accounts for over 80% of sales due to the intravenous route of administration.
- Major markets include the United States (US), European Union (EU), and emerging markets like China and India.
Key Competitors:
- linezolid (Zyvox)
- vancomycin
- ceftaroline
Daptomycin occupies a niche, primarily reserved for resistant gram-positive infections, limiting competition but also restricting market penetration compared to broad-spectrum antibiotics.
Regulatory Landscape:
- FDA approved in 2003.
- Pending or approved generic versions in select markets have begun to erode brand market share.
- No recent significant updates to label restrictions or indications.
Usage Trends
- Rising antibiotic resistance, especially methicillin-resistant Staphylococcus aureus (MRSA), sustains demand.
- Cardiovascular infection indications maintain consistent use.
- The trend toward stewardship programs restrains overuse, potentially limiting growth.
Pricing Dynamics
Current Pricing (US):
- Wholesale Acquisition Cost (WAC): approximately $1,200 - $1,400 per 250 mg vial.
- Average treatment course (based on typical dosing 4-6 mg/kg daily for 7-14 days) costs $10,000 - $25,000.
- Price varies by quantity, service provider, and payer contracts.
Comparison with Competitors:
| Drug |
Typical Course Cost |
Main Indications |
| Daptomycin |
$10,000 - $25,000 |
MRSA, VRE infections |
| Linezolid |
$8,000 - $20,000 |
MRSA, VRE, pneumonia |
| Vancomycin |
$500 - $2,000 per course |
Broad gram-positive infections |
The high cost positions daptomycin as a premium product, often reimbursed highly in hospital settings.
Price Projections (2024-2030)
Assumptions:
- Demand maintains with annual growth rate of 3-5%, driven by resistant infection cases.
- Competition increases as generics emerge, pressuring prices downward.
- New patent expirations and biosimilar entries may occur by 2026-2028.
2024-2025:
Prices are expected to remain stable with minor reductions (~5%) due to increased competition and payer negotiations.
2026-2028:
Potential for a 10-15% decline in WAC prices if biosimilar versions or generics gain approval in the US and EU (e.g., via approved biosimilars to daptomycin). The exact impact depends on regulatory pathways and market acceptance.
2029-2030:
Prices could stabilize at 20-30% below current levels as market penetration by lower-cost alternatives increases, especially in emerging markets. Payers will seek cost savings, further pressuring list prices.
Market Drivers & Risks
Drivers:
- Rising antibiotic resistance levels.
- Increased focus on hospital-acquired infections.
- Clinical preference in cases where other antibiotics fail or are contraindicated.
Risks:
- Patent expiration expected in 2027 in key markets, opening for generics.
- Stringent antimicrobial stewardship reducing overall volume growth.
- Development of newer drugs with similar efficacy at lower cost.
Key Takeaways
- The global daptomycin market is approximately $500 million, with US making up most sales.
- Prices currently range around $1,200 - $1,400 per vial.
- Demand growth persists due to resistant infections, but pricing pressure is expected from generics and biosimilars starting late 2020s.
- Price declines of 20-30% are probable over the next five years, influenced by patent expiry and market competition.
- The potential for improved treatment protocols or new indications could influence long-term demand positively.
FAQs
1. When will patent expiration likely impact daptomycin prices?
Patent expiration in the US is expected around 2027, opening the market for generics and biosimilars, leading to price reductions from 2028 onwards.
2. How much could prices drop if biosimilars enter the market?
Prices could decline by 15-25%, depending on biosimilar acceptance, regulatory approvals, and competitive pricing strategies.
3. Which factors could extend the product's market life?
Development of new indications, resistance patterns increasing usage, and limited alternatives could sustain demand beyond patent expiry.
4. Are there regional differences in pricing?
Yes, prices are generally higher in the US compared to Europe and emerging markets, influenced by healthcare system structures, reimbursement policies, and local competition.
5. How might emerging resistance influence future demand?
Increasing resistance to alternatives like vancomycin supports ongoing demand for daptomycin where it remains effective, although stewardship policies may limit volume growth.
References
- [1] Global Antibiotics Market Size & Growth Report, 2022.
- [2] FDA Drug Approvals and Label Updates, 2003-2023.
- [3] Price Data for IV Antibiotics, US Wholesale Acquisition Cost, 2023.
- [4] Industry Analysis: Antibiotics Market, MarketsandMarkets, 2023.
- [5] Patent and Biosimilar Entry Risks, FDA and EMA filings, 2022-2023.
